ALIF-B 📈 AddLife AB (publ) - Overview
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0014401378
ALIF-B: Laboratory Equipment, Medical Devices, Diagnostics Reagents, Consumables
AddLife AB (publ) is a multifaceted company that, along with its subsidiaries, supplies a wide range of equipment, consumables, and reagents to various sectors, including healthcare, research institutions, colleges, universities, the food industry, and pharmaceutical companies. This diverse customer base benefits from the company's broad portfolio of products and services, which are designed to meet the specific needs of each industry. The company's operations are divided into two main segments: Labtech and Medtech, each catering to distinct markets and requirements.
The Labtech segment is focused on providing solutions and services for diagnostics, biomedical research, and laboratory equipment. This includes a variety of products such as plastic consumables, cell biology tools, reagents, and other laboratory instruments. These offerings are crucial for research and development activities in the life sciences sector, enabling scientists and researchers to conduct experiments, analyze data, and develop new treatments and therapies. By supplying these essential tools and services, AddLife AB (publ) plays a significant role in advancing scientific knowledge and innovation in the field.
In contrast, the Medtech segment is centered on providing medical device products for a range of applications, including surgery, thoracic medicine, neurology, wound care, anesthesia, intensive care, ear, nose, and throat treatments, ostomies, and home healthcare. Additionally, this segment offers assistive technology solutions designed to improve the quality of life for senior citizens and disabled children. These products and services are vital for healthcare providers, enabling them to deliver high-quality patient care and improve outcomes. The Medtech segment's diverse product portfolio reflects the company's commitment to addressing the complex and evolving needs of the healthcare industry.
AddLife AB (publ) has a significant geographical presence, operating in numerous countries across Europe, including Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, and Germany, as well as internationally. This extensive reach allows the company to serve a broad customer base and respond to the unique requirements of different markets. Founded in 1906 and headquartered in Stockholm, Sweden, AddLife AB (publ) has a long history of providing essential products and services to the life sciences and healthcare sectors. With its strong foundation and diversified business model, the company is well-positioned to continue supporting innovation and growth in these critical industries.
Additional Sources for ALIF-B Stock
ALIF-B Stock Overview
Market Cap in USD | 1,500m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception |
ALIF-B Stock Ratings
Growth 5y | 32.6% |
Fundamental | 29.9% |
Dividend | 37.5% |
Rel. Strength Industry | 842 |
Analysts | - |
Fair Price Momentum | 125.04 SEK |
Fair Price DCF | 147.57 SEK |
ALIF-B Dividends
Dividend Yield 12m | 0.38% |
Yield on Cost 5y | 0.71% |
Annual Growth 5y | 38.09% |
Payout Consistency | 69.5% |
ALIF-B Growth Ratios
Growth Correlation 3m | -65.2% |
Growth Correlation 12m | 76.8% |
Growth Correlation 5y | -11.1% |
CAGR 5y | 14.04% |
CAGR/Mean DD 5y | 0.34 |
Sharpe Ratio 12m | 0.76 |
Alpha | 3.96 |
Beta | 0.93 |
Volatility | 51.79% |
Current Volume | 103.1k |
Average Volume 20d | 106.5k |
As of December 21, 2024, the stock is trading at SEK 136.80 with a total of 103,118 shares traded.
Over the past week, the price has changed by -5.39%, over one month by +4.06%, over three months by -15.63% and over the past year by +21.97%.
Neither. Based on ValueRay Fundamental Analyses, AddLife AB (publ) is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 29.86 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ALIF-B as of December 2024 is 125.04. This means that ALIF-B is currently overvalued and has a potential downside of -8.6%.
AddLife AB (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, ALIF-B AddLife AB (publ) will be worth about 137.1 in December 2025. The stock is currently trading at 136.80. This means that the stock has a potential upside of +0.23%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 165.5 | 21% |
Analysts Target Price | - | - |
ValueRay Target Price | 137.1 | 0.2% |